

WHO Expert Committee on Biological Standardization

Report of the seventy-second and seventy-third meetings



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order on line: www.who.int/bookorders).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 3 0

WHO Expert Committee on Biological Standardization

Report of the seventy-second and seventy-third meetings

*This report contains the views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Expert Committee on Biological Standardization: report of the seventy-second and seventy-third meetings

(WHO Technical Report Series, No. 1030)

ISBN 978-92-4-002437-3 (electronic version)

ISBN 978-92-4-002438-0 (print version)

ISSN 0512-3054

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Expert Committee on Biological Standardization: report of the seventy-second and seventy-third meetings. Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1030). Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Contents

Abbreviations	xiv
1. Introduction	1
1.1 Introduction to the seventy-second meeting	1
1.2 Introduction to the seventy-third meeting	2
2. General	5
2.1 Strategic directions in biological standardization: impact of COVID-19	5
2.1.1 WHO collaborations and partnerships related to COVID-19	5
2.1.2 Development of WHO guidance on regulatory considerations in the evaluation of monoclonal antibodies used for the prevention or treatment of COVID-19 and other infectious diseases	6
2.1.3 Update on the use of convalescent plasma as a potential therapy for COVID-19	7
2.1.4 Updating the WHO interim guidance document on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (COVID-19) pandemic and on the collection of COVID-19 convalescent plasma	8
2.1.5 Issues around the implementation and use of WHO international standards	10
2.2 Vaccines and biotherapeutics: recent and planned activities in biological standardization	11
2.2.1 Overview	11
2.3 Blood products and in vitro diagnostics: recent and planned activities in biological standardization	13
2.3.1 Product-specific reference materials for blood coagulation factors VIII and IX	13
2.3.2 Development of guidance on the centralization of blood donation testing and processing	14
2.3.3 Development of a WHO white paper on increasing access to PDMPs in LMIC	15
2.3.4 Reference materials for <i>Plasmodium</i> spp. diagnostics	16
2.4 Feedback from custodian laboratories	17
2.4.1 Developments and scientific issues identified by custodians of WHO international reference standards	17
2.5 Cross-cutting activities of other WHO committees and groups	20
2.5.1 Feedback from the 55th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations	20
2.5.2 Good reliance practices in regulatory decision-making for medical products	21
2.5.3 Good regulatory practices for regulatory oversight of medical products	21
2.5.4 Update on the WHO-listed authorities framework	22
2.5.5 Progress report from the Global Advisory Committee on Vaccine Safety	22
2.5.6 Update on INN nomenclature for biologicals	23
2.5.7 Recent WHO activities in relation to snakebite envenoming	24
2.6 General matters of the Committee	25
2.6.1 Procedural aspects of WHO biological standardization activities	25

3. International Recommendations, Guidelines and other matters related to the manufacture, quality control and evaluation of biological products	26
3.1 Biotherapeutics other than blood products	26
3.1.1 Development of WHO guidance on regulatory considerations in the evaluation of monoclonal antibodies used for the prevention or treatment of infectious diseases	26
3.1.2 Development of WHO guidance on the quality, safety and efficacy of respiratory syncytial virus monoclonal antibodies	28
3.1.3 Outcomes of a WHO survey on the evolving regulatory landscape for similar biotherapeutic products	29
3.1.4 Revision of the WHO Guidelines on evaluation of similar biotherapeutic products (SBPs)	30
3.2 In vitro diagnostics	31
3.2.1 Collaborative procedure between the World Health Organization and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified in vitro diagnostics	31
3.3 Vaccines and related substances	32
3.3.1 Recommendations to assure the quality, safety and efficacy of typhoid conjugate vaccines	32
3.3.2 Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines (inactivated)	34
3.3.3 Revision of the WHO Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (oral, live, attenuated)	35
3.3.4 Amendment to the WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines	36
3.3.5 Development of WHO guidance on regulatory considerations in the evaluation of messenger RNA vaccines	38
4. International reference materials – biotherapeutics other than blood products	40
4.1 WHO international reference standards for biotherapeutics other than blood products	40
4.1.1 Third WHO International Standard for interferon alpha 2b	40
4.1.2 First WHO International Standard for bevacizumab	41
4.1.3 First WHO International Standard for trastuzumab	42
4.1.4 Sixth WHO International Standard for chorionic gonadotrophin (human)	43
4.2 Proposed new projects and updates – biotherapeutics other than blood products	45
4.2.1 Proposed First WHO International Standard for vascular endothelial growth factor 165 (human)	45
4.2.2 Proposed Fourth WHO International Standard for thyroid-stimulating hormone (human, pituitary)	45
4.2.3 Proposed Sixth WHO International Standard for follicle-stimulating hormone and luteinizing hormone (human, urinary)	46
5. International reference materials – blood products and related substances	48
5.1 WHO international reference standards for blood products and related substances	48

5.1.1	WHO International Reference Reagent for anti-human platelet antigen-15b immunoglobulin G (human)	48
5.2	Proposed new projects and updates – blood products and related substances	49
5.2.1	Proposed Second WHO International Standard for blood coagulation factor XIII plasma	49
5.2.2	Proposed Ninth WHO International Standard for blood coagulation factor VIII concentrate	50
6.	International reference materials – cellular and gene therapies	52
6.1	Proposed new projects and updates – cellular and gene therapies	52
6.1.1	Update on the development of a First WHO International Reference Reagent for mesenchymal stromal cell identity for flow cytometry	52
6.1.2	Proposed First WHO International Standard for mesenchymal stromal cells	53
7.	International reference materials – in vitro diagnostics	54
7.1	WHO International reference standards for in vitro diagnostics	54
7.1.1	Second WHO International Standard for insulin-like growth factor 1 (recombinant, human)	54
7.1.2	First WHO International Standard for herpes simplex virus type 1 DNA for NAT-based assays; and First WHO International Standard for herpes simplex virus type 2 DNA for NAT-based assays	55
7.1.3	First WHO International Standard for West Nile virus lineage 1 RNA for NAT-based assays; and WHO International Reference Reagent for West Nile virus lineage 2 RNA for NAT-based assays	56
7.2	Proposed new projects and updates – in vitro diagnostics	57
7.2.1	Proposed First WHO International Standard for anti-β2GPI immunoglobulin G autoantibodies	57
7.2.2	Proposed First WHO International Standard for epidermal growth factor receptor genomic variant C797S	58
7.2.3	Proposed First WHO International Standard for FMS-like tyrosine kinase 3 genomic variant FLT3-ITD	59
7.2.4	Proposed First WHO International Standard for <i>Huaiyangshan banyangvirus</i> RNA for NAT-based assays	60
8.	International reference materials – standards for use in high-throughput sequencing technologies	62
8.1	WHO International reference standards for use in high-throughput sequencing technologies	62
8.1.1	WHO international reference reagents for adventitious virus detection in biological products by high-throughput sequencing	62
8.2	Proposed new projects and updates – standards for use in high-throughput sequencing technologies	63
8.2.1	Proposed WHO international reference reagents for DNA extraction for microbiome analysis	63
9.	International reference materials – standards for use in public health emergencies	65
9.1	WHO international reference standards for use in public health emergencies	65
9.1.1	First WHO International Standard for SARS-CoV-2 RNA for NAT-based assays	65

9.1.2	First WHO International Standard for anti-SARS-CoV-2 immunoglobulin; and First WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin	66
9.2	Proposed new projects and updates – standards for use in public health emergencies	68
9.2.1	Proposed First WHO International Standard for SARS-CoV-2 antigen	68
10.	International reference materials – vaccines and related substances	70
10.1	WHO International reference standards for vaccines and related substances	70
10.1.1	First WHO International Standard for anti-MERS-CoV immunoglobulin G (human)	70
10.2	Proposed new projects and updates – vaccines and related substances	71
10.2.1	Proposed Second WHO International Standard for meningococcal serogroup C polysaccharide	71
Annex 1		
	WHO Recommendations, Guidelines and other documents related to the manufacture, quality control and evaluation of biological products	73
Annex 2		
	Recommendations to assure the quality, safety and efficacy of typhoid conjugate vaccines Replacement of Annex 3 of WHO Technical Report Series, No. 987	79
Annex 3		
	Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines (inactivated)	161
Annex 4		
	Collaborative procedure between the World Health Organization and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified in vitro diagnostics	225
Annex 5		
	New and replacement WHO international reference standards for biological products	267

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>